CIC
MLYS icon

Cornercap Investment Counsel’s Mineralys Therapeutics MLYS Stock Holding History

Cornercap Investment Counsel’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,209
Closed -$191K – 646
2023
Q4 		$191K Buy
+22,209
New +$174K 0.03% 536

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Cornercap Investment Counsel's MLYS Position: Q1 2024 in Review

Cornercap Investment Counsel sold out of Mineralys Therapeutics (MLYS) in Q1 2024, closing a stake of 22,209 shares — an estimated $191K sold.

Cornercap Investment Counsel first reported a position in MLYS in Q4 2023 and held it in 1 quarter. The position peaked at $191K in Q4 2023. 92 funds tracked by Wall St. Rank hold MLYS as of Q1 2024.

  • Cornercap Investment Counsel reported no remaining Mineralys Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 22,209 Mineralys Therapeutics shares in Q1 2024, an estimated $191K.
  • Cornercap Investment Counsel first reported a position in Mineralys Therapeutics in Q4 2023 and held it in 1 quarter.
  • Cornercap Investment Counsel's Mineralys Therapeutics position peaked at $191K in Q4 2023.
  • 92 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2024.

Based on Cornercap Investment Counsel's 13F filing for Q1 2024, filed 10 May 2024.